Compare · BNTX vs IKT
BNTX vs IKT
Side-by-side comparison of BioNTech SE (BNTX) and Inhibikase Therapeutics Inc. (IKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and IKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $20.34B, about 109.8x IKT ($185.2M).
- BNTX has been more active in the news (4 items in the past 4 weeks vs 3 for IKT).
- BNTX has more recent analyst coverage (25 ratings vs 8 for IKT).
- Company
- BioNTech SE
- Inhibikase Therapeutics Inc.
- Price
- -
- -
- Market cap
- $20.34B
- $185.2M
- 1M return
- -9.77%
- -
- 1Y return
- -16.14%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 8
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Inhibikase Therapeutics Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
- SEC Form 6-K filed by BioNTech SE
Latest IKT
- SEC Form 10-Q filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
- SEC Form 4 filed by Inhibikase Therapeutics Inc.
- SEC Form 3 filed by Inhibikase Therapeutics Inc.
- SEC Form 8-K filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
- Chardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price target
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)